Persistence and Evolution of SARS-CoV-2 in an Immunocompromised Host

N Engl J Med. 2020 Dec 3;383(23):2291-2293. doi: 10.1056/NEJMc2031364. Epub 2020 Nov 11.

Authors

Bina Choi¹, Manish C Choudhary¹, James Regan¹, Jeffrey A Sparks¹, Robert F Padera¹, Xueting Qiu², Isaac H Solomon¹, Hsiao-Hsuan Kuo³, Julie Boucau³, Kathryn Bowman³, U Das Adhikari³, Marisa L Winkler¹, Alisa A Mueller¹, Tiffany Y-T Hsu¹, Michaël Desjardins¹, Lindsey R Baden¹, Brian T Chan¹, Bruce D Walker³, Mathias Lichterfeld¹, Manfred Brigl¹, Douglas S Kwon³, Sanjat Kanjilal¹, Eugene T Richardson⁴, A Helena Jonsson¹, Galit Alter⁵, Amy K Barczak⁵, William P Hanage², Xu G Yu⁵, Gaurav D Gaiha⁵, Michael S Seaman⁶, Manuela Cernadas¹, Jonathan Z Li¹

Affiliations

¹ Brigham and Women's Hospital, Boston, MA.
² Harvard T.H. Chan School of Public Health, Boston, MA.
³ Ragon Institute of MGH, MIT, and Harvard, Cambridge, MA.
⁴ Harvard Medical School, Boston, MA.
⁵ Ragon Institute of MGH, MIT and Harvard, Cambridge, MA.
⁶ Beth Israel Deaconess Medical Center, Boston, MA.

No abstract available

Publication types

Case Reports
Letter
Research Support, Non-U.S. Gov't

MeSH terms

Antiphospholipid Syndrome / complications*
COVID-19 / complications*
COVID-19 / diagnosis
Fatal Outcome
Humans
Immunocompromised Host*
Male
Middle Aged
SARS-CoV-2 / isolation & purification
Viral Load

Grants and funding